Follow
Pierpaolo Correale
Pierpaolo Correale
Oncoimmunology, Oncology Unit, Grand Metropolitan BMM Hospital, Reggio Calabria, Italy
No verified email
Title
Cited by
Cited by
Year
In vitro generation of human cytotoxic T lymphocytes specific for peptides derived from prostate-specific antigen
P Correale, C Nieroda, S Zaremba, M Zhu, J Schlom, KY Tsang, ...
Journal of the National Cancer Institute 89 (4), 293-300, 1997
3341997
Regulatory (FoxP3+) T-cell tumor infiltration is a favorable prognostic factor in advanced colon cancer patients undergoing chemo or chemoimmunotherapy
P Correale, MS Rotundo, MT Del Vecchio, C Remondo, C Migali, ...
Journal of immunotherapy 33 (4), 435-441, 2010
2492010
Chemo-immunotherapy of metastatic colorectal carcinoma with gemcitabine plus FOLFOX 4 followed by subcutaneous granulocyte macrophage colony-stimulating factor and interleukin …
P Correale, MG Cusi, KY Tsang, MT Del Vecchio, S Marsili, ML Placa, ...
Journal of Clinical Oncology 23 (35), 8950-8958, 2005
2012005
Generation of human cytolytic T lymphocyte lines directed against prostate-specific antigen (PSA) employing a PSA oligoepitope peptide
P Correale, K Walmsley, S Zaremba, MZ Zhu, J Schlom, KY Tsang
The Journal of Immunology 161 (6), 3186-3194, 1998
1821998
Role of gemcitabine-based combination therapy in the management of advanced pancreatic cancer: a meta-analysis of randomised trials
D Ciliberto, C Botta, P Correale, M Rossi, M Caraglia, P Tassone, ...
European journal of cancer 49 (3), 593-603, 2013
1682013
Adjuvant epirubicin with or without ifosfamide for adult soft-tissue sarcoma
R Petrioli, A Coratti, P Correale, C D’Aniello, L Grimaldi, G Tanzini, ...
American journal of clinical oncology 25 (5), 468-473, 2002
1312002
Systemic inflammatory status at baseline predicts bevacizumab benefit in advanced non-small cell lung cancer patients
C Botta, V Barbieri, D Ciliberto, A Rossi, D Rocco, R Addeo, N Staropoli, ...
Cancer biology & therapy 14 (6), 469-475, 2013
1072013
Immunity feedback and clinical outcome in colon cancer patients undergoing chemoimmunotherapy with gemcitabine+ FOLFOX followed by subcutaneous granulocyte macrophage colony …
P Correale, P Tagliaferri, A Fioravanti, MT Del Vecchio, C Remondo, ...
Clinical Cancer Research 14 (13), 4192-4199, 2008
972008
Treatment of colon and breast carcinoma cells with 5‐fluorouracil enhances expression of carcinoembryonic antigen and susceptibility to HLA‐A (*) 02.01 restricted, CEA‐peptide …
P Correale, A Aquino, A Giuliani, M Pellegrini, L Micheli, MG Cusi, ...
International journal of cancer 104 (4), 437-445, 2003
962003
HLA-B* 44 and C* 01 prevalence correlates with Covid19 spreading across Italy
P Correale, L Mutti, F Pentimalli, G Baglio, RE Saladino, P Sileri, ...
International journal of molecular sciences 21 (15), 5205, 2020
942020
Cetuximab±chemotherapy enhances dendritic cell‐mediated phagocytosis of colon cancer cells and ignites a highly efficient colon cancer antigen‐specific cytotoxic T‐cell …
P Correale, C Botta, MG Cusi, MT Del Vecchio, MM De Santi, ...
International journal of cancer 130 (7), 1577-1589, 2012
942012
Dendritic cell-mediated cross-presentation of antigens derived from colon carcinoma cells exposed to a highly cytotoxic multidrug regimen with gemcitabine, oxaliplatin, 5 …
P Correale, MG Cusi, MT Del Vecchio, A Aquino, S Prete, KY Tsang, ...
The Journal of Immunology 175 (2), 820-828, 2005
942005
Tumor infiltration by T lymphocytes expressing chemokine receptor 7 (CCR7) is predictive of favorable outcome in patients with advanced colorectal carcinoma
P Correale, MS Rotundo, C Botta, MT Del Vecchio, C Ginanneschi, ...
Clinical cancer research 18 (3), 850-857, 2012
902012
Cytotoxic drugs up-regulate epidermal growth factor receptor (EGFR) expression in colon cancer cells and enhance their susceptibility to EGFR-targeted antibody-dependent cell …
P Correale, M Marra, C Remondo, C Migali, G Misso, FP Arcuri, ...
European journal of cancer 46 (9), 1703-1711, 2010
882010
Phenotypic stability of a cytotoxic T-cell line directed against an immunodominant epitope of human carcinoembryonic antigen.
KY Tsang, M Zhu, CA Nieroda, P Correale, S Zaremba, JM Hamilton, ...
Clinical cancer research: an official journal of the American Association …, 1997
861997
Exogenous antigen targeted to FcγRI on myeloid cells is presented in association with MHC class I
PK Wallace, KY Tsang, J Goldstein, P Correale, TM Jarry, J Schlom, ...
Journal of immunological methods 248 (1-2), 183-194, 2001
842001
Efficient delivery of DNA to dendritic cells mediated by influenza virosomes
MG Cusi, C Terrosi, GG Savellini, G Di Genova, R Zurbriggen, P Correale
Vaccine 22 (5-6), 735-739, 2004
832004
Myeloid-derived suppressor cells in multiple myeloma: pre-clinical research and translational opportunities
C Botta, A Gullą, P Correale, P Tagliaferri, P Tassone
Frontiers in oncology 4, 348, 2014
772014
Immune-modulating effects of bevacizumab in metastatic non-small-cell lung cancer patients
EC Martino, G Misso, P Pastina, S Costantini, F Vanni, C Gandolfo, ...
Cell death discovery 2 (1), 1-8, 2016
762016
Early magnesium modifications as a surrogate marker of efficacy of cetuximab-based anticancer treatment in KRAS wild-type advanced colorectal cancer patients
B Vincenzi, S Galluzzo, D Santini, L Rocci, F Loupakis, P Correale, ...
Annals of oncology 22 (5), 1141-1146, 2011
762011
The system can't perform the operation now. Try again later.
Articles 1–20